Captrust Financial Advisors Acquires New Shares in CorMedix Inc. (NASDAQ:CRMD)

Captrust Financial Advisors acquired a new stake in shares of CorMedix Inc. (NASDAQ:CRMD) during the 4th quarter, HoldingsChannel.com reports. The firm acquired 11,116 shares of the company’s stock, valued at approximately $90,000.

Several other hedge funds also recently modified their holdings of CRMD. JPMorgan Chase & Co. grew its position in shares of CorMedix by 685.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 194,108 shares of the company’s stock valued at $1,568,000 after buying an additional 169,397 shares during the last quarter. SG Americas Securities LLC raised its stake in CorMedix by 44.5% during the 4th quarter. SG Americas Securities LLC now owns 27,205 shares of the company’s stock worth $220,000 after buying an additional 8,372 shares during the period. Janney Montgomery Scott LLC bought a new stake in CorMedix during the 4th quarter worth approximately $81,000. AlphaMark Advisors LLC increased its holdings in CorMedix by 16.7% during the 4th quarter. AlphaMark Advisors LLC now owns 14,000 shares of the company’s stock worth $113,000 after purchasing an additional 2,000 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new stake in CorMedix during the 4th quarter worth approximately $104,000. Institutional investors and hedge funds own 34.18% of the company’s stock.

CorMedix Price Performance

NASDAQ CRMD opened at $12.26 on Friday. The stock has a market capitalization of $831.53 million, a PE ratio of -15.14 and a beta of 1.54. CorMedix Inc. has a 1 year low of $3.61 and a 1 year high of $13.85. The business’s 50-day moving average is $9.03 and its 200 day moving average is $9.81.

CorMedix (NASDAQ:CRMD) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.05. The firm had revenue of $39.08 million for the quarter, compared to the consensus estimate of $38.90 million. During the same period in the previous year, the firm posted ($0.25) earnings per share. As a group, equities research analysts anticipate that CorMedix Inc. will post -0.32 earnings per share for the current year.

Wall Street Analyst Weigh In

CRMD has been the subject of several recent analyst reports. Needham & Company LLC upped their target price on CorMedix from $12.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, May 7th. D. Boral Capital restated a “buy” rating and set a $15.00 target price on shares of CorMedix in a research report on Tuesday, May 6th. Leerink Partners started coverage on CorMedix in a research report on Friday, March 7th. They issued an “outperform” rating and a $18.00 price objective on the stock. Wall Street Zen upgraded CorMedix from a “sell” rating to a “hold” rating in a research report on Tuesday, April 1st. Finally, Royal Bank of Canada restated an “outperform” rating and set a $12.00 price target on shares of CorMedix in a research report on Wednesday, March 26th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $15.00.

About CorMedix

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.